TransCode Therapeutics (NASDAQ:RNAZ) Sees Heavy Selling pressure: Where is The Bottom?
TransCode Therapeutics (NASDAQ:RNAZ) dropped 29% after the upcoming RNA oncology company priced its initial public offering (IPO) of 6.25 million
Read more
TransCode Therapeutics (NASDAQ:RNAZ)